Ask most people what creatine does and they will tell you it builds muscle. They are not wrong, but they are dramatically incomplete. Creatine monohydrate is the single most extensively studied ergogenic supplement in the history of sports nutrition — with hundreds of randomized controlled trials demonstrating its safety and efficacy for enhancing high-intensity exercise performance, increasing lean mass, and improving strength. The International Society of Sports Nutrition has called creatine "the most effective ergogenic nutritional supplement currently available to athletes" (Kreider et al., 2017).
But reducing creatine to a gym supplement — as both the fitness industry and general public have done — obscures what may be its most consequential applications: neuroprotection, cognitive enhancement, depression treatment, cellular energy support for aging tissues, and metabolic health. Creatine is not merely a sports supplement that has wandered into neuroscience. It is a fundamental cellular energy molecule with applications across the entire spectrum of human physiology.
What creatine is
Creatine is a naturally occurring compound synthesized endogenously from the amino acids arginine, glycine, and methionine — primarily in the liver, kidneys, and pancreas. Approximately 95% of the body's creatine pool (approximately 120-140 g in a 70 kg adult) is stored in skeletal muscle, with the remaining 5% distributed in the brain, heart, and other tissues.
Creatine's biological function is deceptively simple but physiologically indispensable: it serves as a rapid energy buffer, enabling the regeneration of ATP from ADP through the creatine kinase (CK) reaction.
The creatine kinase reaction — phosphocreatine + ADP → creatine + ATP — operates at near-equilibrium, enabling instantaneous ATP regeneration during periods of high energy demand. This reaction is the fastest available mechanism for ATP regeneration — faster than glycolysis, faster than oxidative phosphorylation — and is therefore critical for tissues that require rapid, high-magnitude energy supply: skeletal muscle during intense contraction, cardiac muscle during each heartbeat, and neurons during intense cognitive activity.
Dietary creatine comes primarily from meat and fish — typical omnivorous diets provide approximately 1-2 g/day, while vegetarian and vegan diets provide essentially none. Endogenous synthesis provides an additional 1-2 g/day. The combination of dietary intake and endogenous synthesis maintains the creatine pool, but supplementation (typically 3-5 g/day creatine monohydrate) increases intracellular creatine and phosphocreatine concentrations by approximately 20-40%, enhancing the energy buffering capacity of supplemented tissues.
Creatine and the brain
The brain is an energy-hungry organ: constituting approximately 2% of body mass, it consumes approximately 20% of the body's total ATP production. The brain's creatine kinase system is critical for maintaining neuronal energy supply during periods of intense cognitive demand, and brain creatine levels influence cognitive performance, neuroprotection, and mental health.
Cognitive enhancement. Multiple randomized controlled trials have demonstrated that creatine supplementation improves cognitive performance — particularly in conditions of cognitive stress (sleep deprivation, hypoxia, mental fatigue, and complex task demands). A systematic review by Avgerinos et al. (2018) in Experimental Gerontology found that creatine supplementation improved short-term memory, working memory, and reasoning — effects that were most pronounced in elderly individuals and vegetarians (who have lower baseline brain creatine stores due to absent dietary creatine).
Sleep deprivation. McMorris et al. (2006) demonstrated that creatine supplementation (20 g/day for 5 days) significantly attenuated the cognitive decline produced by 24-36 hours of sleep deprivation — improving executive function, reaction time, and mood compared to placebo. The mechanism involves maintaining brain ATP levels during the metabolic stress of sleep deprivation.
Vegetarian brain creatine. Studies using magnetic resonance spectroscopy (MRS) have demonstrated that vegetarians and vegans have lower brain creatine concentrations compared to omnivores — and that creatine supplementation produces larger cognitive improvements in vegetarians than in omnivores, reflecting the correction of a relative deficit.
Depression and mental health. An emerging body of research suggests that creatine supplementation may have antidepressant effects — a finding that is consistent with the metabolic theory of depression (which posits that impaired cerebral energy metabolism contributes to depressive pathophysiology) and with the observation that brain creatine levels are reduced in depressive states.
A 2020 randomized, double-blind trial by Kious et al. in the Journal of Affective Disorders demonstrated that creatine supplementation (5 g/day for 8 weeks) as an adjunct to SSRI therapy produced significantly greater improvement in depression scores compared to SSRI + placebo in women with major depressive disorder. Creatine supplementation reduced depression scores by approximately 50% — an effect size comparable to augmentation strategies used in treatment-resistant depression.
The biological rationale is compelling: depression is associated with impaired cerebral energy metabolism (reduced ATP turnover, mitochondrial dysfunction, altered creatine kinase activity). Creatine supplementation increases the brain's phosphocreatine reserves, enhancing the capacity for rapid ATP regeneration and potentially correcting the energy deficit that contributes to depressive symptoms.
Traumatic brain injury (TBI). The brain is highly vulnerable to energy depletion following traumatic injury, and the creatine kinase system is critical for maintaining neuronal survival during the metabolic crisis that follows TBI. Animal studies have consistently demonstrated neuroprotective effects of creatine supplementation administered before or shortly after experimental TBI — reducing lesion size, improving behavioral outcomes, and attenuating mitochondrial damage.
Two small clinical trials in children with TBI demonstrated that creatine supplementation (0.4 g/kg/day for 6 months) reduced post-traumatic headaches, dizziness, and fatigue and improved cognitive recovery compared to placebo (Sakellaris et al., 2006, 2008). While these trials were small and require replication, the consistency with animal models and the favorable safety profile of creatine make this a promising area for future investigation.
Creatine and aging
The aging process is characterized by progressive decline in cellular energy capacity — reduced mitochondrial function, decreased muscle mass (sarcopenia), cognitive decline, and reduced physical function. Creatine supplementation addresses multiple aspects of this energy decline:
Sarcopenia. The age-related loss of muscle mass and strength — sarcopenia — is one of the most significant contributors to falls, fractures, disability, and loss of independence in elderly populations. Resistance training is the primary intervention for sarcopenia, and creatine supplementation enhances the benefits of resistance training in older adults more consistently than in younger populations.
A meta-analysis by Devries & Phillips (2014) in the journal PLOS ONE, analyzing 22 studies of creatine supplementation combined with resistance training in adults over 50, found that creatine significantly enhanced gains in lean mass, upper body strength, and lower body strength compared to resistance training alone. The magnitude of benefit was clinically meaningful — approximately 1.4 kg additional lean mass and 3.4 kg additional strength — and the benefit appeared to increase with age.
Bone health. Emerging evidence suggests that creatine supplementation may benefit bone metabolism. Creatine is present in bone cells (osteoblasts and osteoclasts) and may influence bone mineral density through effects on muscle-bone crosstalk, mechanical loading, and cellular energy supply. A 12-month trial by Chilibeck et al. (2015) found a trend toward reduced bone resorption markers with creatine supplementation in postmenopausal women.
Cognitive aging. The cognitive benefits of creatine supplementation described above are particularly relevant for aging populations, where age-related declines in brain creatine and phosphocreatine levels contribute to cognitive deterioration. The combination of cognitive benefits, neuroprotective effects, and enhancement of exercise adaptation makes creatine a uniquely multifaceted intervention for healthy aging.
Creatine in clinical medicine
Beyond aging and neuroprotection, creatine has been investigated in several clinical contexts:
Heart failure. The failing heart has depleted creatine and phosphocreatine stores — reduced by approximately 50-60% compared to healthy myocardium. This energy depletion limits the heart's contractile reserve and contributes to exercise intolerance. Small clinical trials of creatine supplementation in heart failure patients have demonstrated improved handgrip strength, reduced fatigue, and enhanced exercise capacity. The creatine kinase energy shuttle is critical for cardiac function, and replenishing the myocardial creatine pool through supplementation is a rational therapeutic approach that warrants larger trials (Neubauer, 2007).
Diabetes and glycemic control. Creatine supplementation combined with exercise improves glycemic control more than exercise alone. A 12-week randomized trial by Gualano et al. (2011) in Medicine & Science in Sports & Exercise demonstrated that creatine supplementation combined with exercise training improved glucose tolerance, HbA1c, and insulin sensitivity in Type 2 diabetic patients compared to exercise alone. The mechanism involves AMPK activation, enhanced glucose transporter (GLUT4) translocation, and increased muscle mass (which serves as a glucose disposal organ).
Fibromyalgia. Given the evidence for impaired energy metabolism in fibromyalgia and the fatigue-predominant symptom profile of the condition, creatine supplementation has been investigated as a potential intervention. A pilot study by Alves et al. (2013) found that creatine supplementation improved upper and lower body muscle function and reduced pain in fibromyalgia patients.
Safety: the most studied supplement
Creatine monohydrate is arguably the most extensively studied supplement for safety in the history of nutritional science. The safety evidence includes:
- Hundreds of clinical trials involving thousands of participants across all age groups (from children to elderly adults)
- Studies of durations from days to 5+ years
- Assessment in healthy individuals, athletes, patients with various clinical conditions, and special populations
- Consistent finding of safety at standard doses (3-5 g/day)
Kidney function. The persistent myth that creatine damages kidneys originated from the observation that creatine supplementation increases serum creatinine levels — creatinine being a metabolic byproduct of creatine that is routinely used as a marker of kidney function. However, the elevated creatinine in creatine users reflects increased creatine turnover, NOT impaired kidney function. Multiple studies using direct measures of kidney function (GFR, cystatin C, renal imaging) have confirmed that creatine supplementation at standard doses does not adversely affect kidney function in healthy individuals or in patients with a single kidney (Gualano et al., 2008; Kim et al., 2011).
The only population requiring caution is patients with pre-existing severe kidney disease (GFR <30), where any additional metabolic load on the kidneys warrants medical supervision.
Dehydration and cramping. The claim that creatine causes dehydration and muscle cramping has been conclusively refuted. In fact, creatine supplementation increases total body water (creatine is an osmolyte that draws water into muscle cells), and multiple studies in athletes have found that creatine supplementation either has no effect on or actually reduces the incidence of muscle cramps and heat-related illness (Lopez et al., 2009).
Hair loss. A single study by van der Merwe et al. (2009) found that creatine loading increased dihydrotestosterone (DHT) levels in college rugby players. This study has been widely cited as evidence that creatine causes hair loss. However, the study did not measure hair loss, subsequent studies have not replicated the DHT finding, and no clinical study has ever documented creatine-induced alopecia. The claim, while persistent, is not supported by the weight of evidence.
Practical recommendations
Form. Creatine monohydrate is the recommended form — the form used in the vast majority of clinical research, the least expensive, and the best-established for safety and efficacy. Alternative forms (creatine hydrochloride, creatine ethyl ester, buffered creatine) are marketed as superior but have not demonstrated superiority over monohydrate in comparative studies.
Dose. Standard maintenance dosing: 3-5 g/day. Loading protocol (optional): 20 g/day divided into 4 doses for 5-7 days, followed by 3-5 g/day maintenance. Loading saturates muscle creatine stores faster but is not required — maintenance dosing alone achieves saturation within approximately 3-4 weeks.
Timing. Post-exercise may be marginally superior to pre-exercise for muscle creatine uptake, but the difference is small. Consistency (daily supplementation) matters far more than timing.
Population considerations. Vegetarians and vegans may benefit most from creatine supplementation due to lower baseline creatine stores. Older adults may benefit disproportionately from the combination of creatine supplementation and resistance training for sarcopenia prevention.
Creatine monohydrate is inexpensive, safe, and effective — for muscle, for brain, for aging, and potentially for clinical conditions characterized by energy depletion. That the "gym supplement" framing has limited its recognition in clinical medicine is one of the more unfortunate examples of how marketing categories can constrain scientific thinking.
References
- Avgerinos, K. I., et al. (2018). Effects of creatine supplementation on cognitive function. Experimental Gerontology, 108, 166–173.
- Chilibeck, P. D., et al. (2015). Effect of creatine supplementation during resistance training on bone health. Medicine & Science in Sports & Exercise, 47(8), 1587–1595.
- Devries, M. C., & Phillips, S. M. (2014). Creatine supplementation during resistance training in older adults. PLOS ONE, 9(2), e86904.
- Gualano, B., et al. (2011). Creatine supplementation and resistance training in vulnerable older women. Medicine & Science in Sports & Exercise, 43(8), 1413–1423.
- Kreider, R. B., et al. (2017). International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation. JISSN, 14, 18.
- Neubauer, S. (2007). The failing heart — an engine out of fuel. NEJM, 356(11), 1140–1151.
- Sakellaris, G., et al. (2006). Prevention of complications related to traumatic brain injury in children with creatine administration. Journal of Trauma, 61(2), 322–329.
Creatine and female health
Historically, creatine research has disproportionately enrolled male subjects — a bias that has contributed to the perception of creatine as a "male gym supplement" and has left significant knowledge gaps regarding creatine's effects in women. This is changing:
Hormonal fluctuations. Women's creatine metabolism is influenced by hormonal fluctuations across the menstrual cycle. Estrogen stimulates endogenous creatine synthesis, while progesterone may reduce it. These fluctuations suggest that women's creatine needs may vary across the cycle and that supplementation may be particularly beneficial during luteal phases when progesterone is dominant.
Post-menopause. The decline in estrogen production during menopause reduces endogenous creatine synthesis, potentially contributing to the accelerated muscle mass loss and bone density decline observed in postmenopausal women. Creatine supplementation combined with resistance training in postmenopausal women has shown promising results for preserving lean mass and improving bone health markers — addressing the same physiological decline through a different mechanism than hormone replacement therapy.
Pregnancy and lactation. Creatine is critical for fetal development — the developing brain and other tissues rely heavily on creatine kinase-mediated energy buffering. Animal studies have demonstrated that maternal creatine supplementation improves fetal outcomes in complicated pregnancies (including hypoxic events). Research on creatine supplementation during human pregnancy is in early stages but represents a promising area of investigation (Dickinson et al., 2014).
Depression (female-specific evidence). The majority of clinical trials demonstrating antidepressant effects of creatine have been conducted in women — where the combination of creatine's energy-buffering effects with the higher prevalence of depression in women creates a particularly relevant therapeutic intersection.
The broader picture: cellular energy medicine
Creatine supplementation exemplifies a broader paradigm in medicine that is only now gaining traction: cellular energy medicine. Many chronic diseases — depression, heart failure, neurodegenerative disease, chronic fatigue, fibromyalgia, age-related functional decline — share a common feature: impaired cellular energy metabolism. The failing brain, the failing heart, and the aging muscle are all, fundamentally, organs running out of fuel.
Creatine addresses this energy deficit at its most fundamental level: the ATP regeneration reaction. It does not treat symptoms. It does not modulate neurotransmitters (directly). It does not suppress inflammation (directly). It simply provides the substrate for the most basic energy transaction in human biochemistry — the conversion of ADP back to ATP, the molecule that powers everything.
The simplicity of this mechanism is both its strength and its marketing challenge. In a supplement market that rewards complexity, novelty, and proprietary formulations, creatine's simplicity — it is a white powder that costs $0.05 per dose — works against it commercially. But simplicity and efficacy are not mutually exclusive. Sometimes the best intervention is the simplest one.
Creatine monohydrate may be the most underappreciated therapeutic molecule in modern medicine — not because the evidence is lacking, but because the evidence has been trapped in the wrong category. It is time to bring it home from the gym to the clinic, from the weight room to the neurology department, from the supplement aisle to the physician's desk. The science has been ready for years. The culture is finally catching up.
Creatine and neurological disease
Active clinical investigation is examining creatine's role in neurodegenerative disease — conditions characterized by progressive neuronal energy failure:
Parkinson's disease. The NINDS NET-PD trial examined creatine supplementation in early Parkinson's disease. While the initial phase II results were promising, the large phase III trial (1,741 participants, 10 g/day creatine vs. placebo) was halted for futility after a median of 5 years of follow-up — creatine did not slow disease progression. Despite the negative primary outcome, the trial provided valuable safety data: 10 g/day of creatine for up to 5 years was well-tolerated in elderly patients with neurodegenerative disease.
Huntington's disease. The CREST-E trial examined 30 g/day of creatine in Huntington's disease — an extraordinarily high dose reflecting the severity of the mitochondrial energy deficit in this condition. Like the Parkinson's trial, the results were negative for clinical progression. However, the safety data was reassuring even at this extreme dose.
These negative results in established neurodegenerative disease should not be interpreted as evidence against creatine's neuroprotective potential. Rather, they suggest that once neurodegeneration is established, energy supplementation alone may be insufficient to reverse progressive neuronal loss. The therapeutic window may be in prevention and early intervention — a hypothesis consistent with the cognitive benefits demonstrated in non-diseased populations and the TBI protection demonstrated in animal models.